Yalcin, A. D. Et Al. 2013. Effects of omalizumab on eosinophil cationic peptide, 25-hydroxyvitamin-D, IL-1 beta and sCD200 in cases of Samter's syndrome: 36 months follow-up. IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY , vol.35, no.4 , 524-527.

Yalcin, A. D., Ucar, S., GÜMÜŞLÜ, S., & Strauss, L. G., (2013). Effects of omalizumab on eosinophil cationic peptide, 25-hydroxyvitamin-D, IL-1 beta and sCD200 in cases of Samter's syndrome: 36 months follow-up. IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY , vol.35, no.4, 524-527.

Yalcin, Arzu Et Al. "Effects of omalizumab on eosinophil cationic peptide, 25-hydroxyvitamin-D, IL-1 beta and sCD200 in cases of Samter's syndrome: 36 months follow-up," IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY , vol.35, no.4, 524-527, 2013

Yalcin, Arzu D. Et Al. "Effects of omalizumab on eosinophil cationic peptide, 25-hydroxyvitamin-D, IL-1 beta and sCD200 in cases of Samter's syndrome: 36 months follow-up." IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY , vol.35, no.4, pp.524-527, 2013

Yalcin, A. D. Et Al. (2013) . "Effects of omalizumab on eosinophil cationic peptide, 25-hydroxyvitamin-D, IL-1 beta and sCD200 in cases of Samter's syndrome: 36 months follow-up." IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY , vol.35, no.4, pp.524-527.

@article{article, author={Arzu Didem Yalcin Et Al. }, title={Effects of omalizumab on eosinophil cationic peptide, 25-hydroxyvitamin-D, IL-1 beta and sCD200 in cases of Samter's syndrome: 36 months follow-up}, journal={IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY}, year=2013, pages={524-527} }